...
首页> 外文期刊>Surgical infections >Aerosolized Ceftazidime Prophylaxis against Ventilator-Associated Pneumonia in High-Risk Trauma Patients: Results of a Double-Blind Randomized Study
【24h】

Aerosolized Ceftazidime Prophylaxis against Ventilator-Associated Pneumonia in High-Risk Trauma Patients: Results of a Double-Blind Randomized Study

机译:雾化头孢他啶预防高危创伤患者呼吸机相关性肺炎:一项双盲随机研究的结果

获取原文
获取原文并翻译 | 示例

摘要

Background: Ventilator-associated pneumonia (VAP) is a frequent complication during recovery of severely traumatized patients. The primary objective of this study was to determine if prophylactic administration of aerosolized ceftazidime reduced the incidence of VAP in high-risk injured patients without altering the incidence of other infectious complications. Patients and Methods: This was a single-institution double-blind, randomized trial that compared a seven-day course of aerosolized ceftazidime with placebo. Intubated high-risk patients admitted to the trauma intensive care unit at a large regional trauma center between February 2003 and September 2005 were eligible for enrollment. The main outcome evaluated was the incidence of VAP at two weeks and 30 days. The incidences of multi-drug-resistant infections and other infectious complications were secondary outcomes. Results: A total of 105 patients were randomized, resulting in 52 patients in the placebo arm and 53 patients in the ceftazidime arm. There was no statistical difference between the groups with regard to demographic data, injury severity, calculated risk of VAP, or the number of doses received. In the intention-to-treat analysis, the incidence of VAP at two weeks was 24/52 (46) in the placebo group and 21/53 (40) in the ceftazidime group. The number of patients with VAP at 30 days was 26/52 (50) in the placebo group and 26/53 (49) in the ceftazidime group. There was no statistical difference in the development of multi-drug-resistant VAP or other infectious complications in the two groups. Conclusion: The use of aerosolized ceftazidime did not reduce the rate of VAP in high-risk patients admitted after traumatic injury, but neither did it increase the incidence of other infectious complications. Routine use of prophylactic aerosolized ceftazidime to prevent VAP in trauma patients cannot be recommended.
机译:背景:呼吸机相关性肺炎 (VAP) 是严重创伤患者康复期间的常见并发症。本研究的主要目的是确定预防性使用雾化头孢他啶是否在不改变其他感染并发症发生率的情况下降低高危受伤患者 VAP 的发生率。患者和方法:这是一项单机构双盲随机试验,比较了雾化头孢他啶与安慰剂的 7 天疗程。2003 年 2 月至 2005 年 9 月期间,在大型区域创伤中心创伤重症监护病房收治的插管高危患者有资格入组。评估的主要结局是2周和30天时VAP的发生率。多重耐药感染和其他感染性并发症的发生率是次要结局。结果:共有 105 例患者被随机分配,安慰剂组 52 例,头孢他啶组 53 例。两组之间在人口统计数据、损伤严重程度、计算出的VAP风险或接受的剂量数量方面没有统计学差异。在意向性治疗分析中,安慰剂组两周时VAP的发生率为24/52(46%),头孢他啶组为21/53(40%)。安慰剂组 30 天时 VAP 患者人数为 26/52 (50%),头孢他啶组为 26/53 (49%)。两组多重耐药VAP或其他感染性并发症的发生无统计学差异。结论:使用雾化头孢他啶并未降低创伤后入院的高危患者VAP发生率,但未增加其他感染并发症的发生率。不建议常规使用预防性雾化头孢他啶来预防创伤患者的 VAP。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号